Ultragenyx Pharmaceutical (RARE) Operating Income Growth (3y) (2016 - 2026)
Ultragenyx Pharmaceutical (RARE) Operating Income Growth (3y) (2016 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Op. Inc Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,831.58 Bn | 66,831.30 Bn | - | 16.96% |
| 2 | Nanobiotix | 1,916.61 Bn | 1,916.55 Bn | - | - |
| 3 | Akari Therapeutics | 976.78 Bn | 976.78 Bn | - | - |
| 4 | BeOne Medicines | 471.48 Bn | 466.69 Bn | 1.35 Bn | 38.78% |
| 5 | Vertex Pharmaceuticals | 121.78 Bn | 114.53 Bn | 2.59 Bn | 13.47% |
| 6 | Regeneron Pharmaceuticals | 69.87 Bn | 61.12 Bn | 3.31 Bn | -12.10% |
| 7 | Belite Bio | 63.06 Bn | 63.06 Bn | - | - |
| 8 | Argenx Se | 55.78 Bn | 50.60 Bn | 1.41 Bn | 69.02% |
| 9 | Alnylam Pharmaceuticals | 37.54 Bn | 34.53 Bn | 959.66 Mn | 55.96% |
| 10 | Ultragenyx Pharmaceutical | 2.73 Bn | 2.32 Bn | 106.00 Mn | -3.12% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -3.12% |
| Dec 31, 2025 | 8.03% |
| Sep 30, 2025 | 8.77% |
| Jun 30, 2025 | 8.66% |
| Mar 31, 2025 | -1.53% |
| Dec 31, 2024 | -6.04% |
| Sep 30, 2024 | -13.69% |
| Jun 30, 2024 | -12.02% |
| Mar 31, 2024 | -15.77% |
| Dec 31, 2023 | -8.24% |
| Sep 30, 2023 | -42.34% |
| Jun 30, 2023 | -32.88% |
| Mar 31, 2023 | -8.50% |
| Dec 31, 2022 | -15.53% |
| Sep 30, 2022 | -24.00% |
| Jun 30, 2022 | -7.98% |
| Mar 31, 2022 | -11.26% |
| Dec 31, 2021 | -4.32% |
| Sep 30, 2021 | -0.07% |
| Jun 30, 2021 | 4.45% |